CA2347913A1 - Oral administration of adenosine analogs - Google Patents

Oral administration of adenosine analogs Download PDF

Info

Publication number
CA2347913A1
CA2347913A1 CA002347913A CA2347913A CA2347913A1 CA 2347913 A1 CA2347913 A1 CA 2347913A1 CA 002347913 A CA002347913 A CA 002347913A CA 2347913 A CA2347913 A CA 2347913A CA 2347913 A1 CA2347913 A1 CA 2347913A1
Authority
CA
Canada
Prior art keywords
composition
group
components
analog
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002347913A
Other languages
French (fr)
Other versions
CA2347913C (en
Inventor
Simeon M. Wrenn, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2347913A1 publication Critical patent/CA2347913A1/en
Application granted granted Critical
Publication of CA2347913C publication Critical patent/CA2347913C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Al so disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or table t, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.

Claims (37)

1. A composition comprising:
2'-deoxyadenosine analog which chemically decomposes in an acidic environment of the stomach; and one or more components which inhibit the 2'-deoxyadenosine analog from decomposing in the acidic environment of the stomach by isolating the 2'-deoxyadenosine analog from the acidic environment of the stomach;
wherein the composition is suitable to ba administered orally to a patient.
2. The composition according to claim 1 wherein the 2'-deoxyadenosine analog is pentostatin.
3. The composition according to claim 1 wherein the one or more components of the composition foam an erodible matrix.
4. The composition according to claim 1 wherein the one or more components of the composition include an enteric coating.
5. The composition according io claim 4 wherein the enteric coating comprises a member of the group consisting of hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid osier copolymer.
polyvinyl acetate-phthalate and cellulose acetate phthalate.
6. The composition according to claim 1 wherein the composition is a solid dispersion.
7. The composition according to claim 6 wherein the solid dispersion comprises a carrier selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl-cellulose, phosphatidylcholine, polyoxyethylene hydrogenated castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, ethyl cellulose and stearic acid.
8. The composition according to claim 1 wherein the one or more components of the composition include as ion exchange resin that forms a complex with the adenosine analog.
9. The composition according to claim 1 wherein the one or more components of the composition include injectable micro spheres.
10. The composition according to claim 1 wherein the composition is in a form selected from the group consisting of pill, capsule, liquid, lozenge, and tablet.
11. A method for treating a patient comprising;
orally administering to the patient a pharmaceutically-effective amount of a composition which is adapted for oral administration and comprises:
a 2'-deoxyadenosine analog which chemically decomposes in an acidic environment of the stomach, and one or more components of the composition which inhibit the 2'-deoxy adenosine analog from decomposing in the acidic environment of the stomach by isolating the adenosine analog from the acidic environment of the stomach.
12. The method according to claim 11 wherein the 2'-deoxyadenosine analog is pentostatin.
13. the method according to claim 11 wherein the one or more components of the composition form an erodible matrix.
14. The method according to claim 11 wherein the one or more components of the composition include an enteric coating.
15. The method according to claim 14 wherein the enteric coating comprises a member of the group consisting of hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate.
16. The method according to claim 11 wherein the composition is a solid dispersion.
17. The method according to claim 16 wherein the solid dispersion comprises a carrier selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl - cellulose, phosphatidylcholine, polyoxyethylene hydrogenated, castor oil, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, ethyl cellulose and stearic acid.
18. The method according to claim 11 wherein the one or more components of the composition comprise an ion exchange resin that forms a complex with the adenosine analog.
19. The method according to claim 11 wherein the one or more components of the composition comprise injectable micro spheres.
20. The method according to claim 11 wherein the composition is in a form selected from the group consisting of pill, capsule, liquid, lozenge, and tablet.
21. The method according to claim 11 wherein the patient has a disease selected from the group consisting of hematological malignancies, solid tumors sensitive to adenosine analogs or adenosine deaminase inhibitors, and autoimmune diseases mediated by adenosine or adenosine deaminase.
22. The method according to claim 11 wherein the patient has leukemia.
23. The method according to claim 11 wherein the patient has a leukemia selected francs the group consisting of hairy cell leukemia and chronic lymphocytic leukemia, chronic T-cell lymphoma, acute myelogenous lymphoma, hairy cell leukemia, and chronic lymphocytic leukemia.
24. A method for treating a patient comprising:
orally administering in a controlled-release mechanism to the patient a composition which is adapted for oral administration and comprises:
a 2'-deoxyadenosine analog which chemically decomposes in an acidic environment of the stomach, and one or more components of the composition which inhibit the 2'-deoxyadenosine analog from decomposing in the acidic environment of the stomach by isolating the 2'-deaxyadenosine analog from the acidic environment of the stomach.
25. The method according to claim 24 wherein the 2'-deoxy adenosine analog is pentostatin.
26. The method according to claim 24 wherein the controlled-release mechanism is selected from the group consisting of a reservoir system with a rate-controlling membrane, reservoir system without a rate-controlling membrane, monolithic system, and osmotic pump.
27. The method according to claim 24 wherein the controlled-release mechanism is selected from the group consisting of SODAS, INDAS, IPDAS, MODAS, EFVAS, PRODAS, and DUREDAS.
28. The method according to claim 24 wherein the one or more components of the composition form an erodible matrix.
29. The method according to claim 24 wherein the controlled-release mechanism is selected from the group consisting of a rate-preprogrammed drug delivery system, an activation-modulated drug delivery system, a feedback-regulated drug delivery system, and a site-targeting drug delivery system.
30. The method according to claim 24 wherein the composition includes an enteric coating.
31. The method according to claim 30 wherein the enteric coating comprises a member of the group consisting of hydroxypropyl-methylcellulose phthalate, methacrylic acid-methacrylic acid ester copolymer, polyvinyl acetate-phthalate and cellulose acetate phthalate.
32. The method according to claim 24 wherein the one or more components of the composition include an ion exchange resin that forms a complex with the 2'-deoxyadenosine analog.
33. The method according to claim 24 wherein the one or more components of the composition include injectable micro spheres.
34. The method according to claim 24 wherein the composition is in a form selected from the group consisting of pill, capsule, liquid, lozenge, end tablet.
35. The method according to claim 24 wherein the patient has a disease selected from the group consisting of hematological malignancies, solid tumors sensitive to adenosine analogs or adenosine deaminase inhibitors, and autoimmune diseases mediated by adenosine or adenosine deaminase.
36. The method according to claim 24 wherein the patient has leukemia.
37. A method according to claim 36 wherein the patient has a leukemia selected from the group consisting of hairy cell leukemia, and chronic lymphocytic leukemia, chronic T-cell lymphoma, acute myelogenous lymphoma, hairy cell leukemia, and chronic lymphocytic leukemia.
CA2347913A 1998-11-04 1999-11-01 Oral administration of adenosine analogs Expired - Fee Related CA2347913C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/185,909 US6174873B1 (en) 1998-11-04 1998-11-04 Oral administration of adenosine analogs
US09/185,909 1998-11-04
PCT/US1999/025676 WO2000025758A1 (en) 1998-11-04 1999-11-01 Oral administration of adenosine analogs

Publications (2)

Publication Number Publication Date
CA2347913A1 true CA2347913A1 (en) 2000-05-11
CA2347913C CA2347913C (en) 2010-09-14

Family

ID=22682923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2347913A Expired - Fee Related CA2347913C (en) 1998-11-04 1999-11-01 Oral administration of adenosine analogs

Country Status (13)

Country Link
US (1) US6174873B1 (en)
EP (1) EP1126828B1 (en)
JP (2) JP5523647B2 (en)
AT (1) ATE427103T1 (en)
AU (1) AU774055B2 (en)
CA (1) CA2347913C (en)
DE (1) DE69940674D1 (en)
DK (1) DK1126828T3 (en)
ES (1) ES2322724T3 (en)
IL (2) IL142801A0 (en)
MX (1) MXPA01004547A (en)
PT (1) PT1126828E (en)
WO (1) WO2000025758A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100532898B1 (en) 1997-12-11 2005-12-05 쉐링 악티엔게젤샤프트 Purification Method for Producing Fludarabine Phosphate
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
AU2031799A (en) 1998-01-14 1999-08-02 Uab Research Foundation, The Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
JP4638098B2 (en) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド Cancer treatment
EP1200102A1 (en) * 1999-07-22 2002-05-02 Supergen, Inc. Methods for treating autoimmune diseases
AUPR018900A0 (en) * 2000-09-18 2000-10-12 Fh Faulding Pty Limited Pamidronate solution
EP1311262A4 (en) * 2000-07-28 2005-06-01 Cancer Rec Tech Ltd Cancer treatment by combination therapy
ATE476968T1 (en) * 2000-09-06 2010-08-15 Mitsubishi Tanabe Pharma Corp GRANULE PREPARATIONS FOR ORAL ADMINISTRATION
EP1318818A4 (en) * 2000-09-18 2004-09-29 Faulding F H & Co Ltd Diphosphonate solutions
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
EP1429728A1 (en) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
DE10164510A1 (en) * 2001-12-20 2003-07-10 Schering Ag Oral Fludara pure formulation with rapid release of the active ingredient
US20030124178A1 (en) * 2001-12-28 2003-07-03 Haley Jeffrey T. Soft, adherent, soluble oral patch
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
RU2004123637A (en) * 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) PHARMACEUTICAL MEDICINAL FORMS OF CONTROLLED RELEASE OF THE CHOLESTEROL PROTEIN PROTEIN INHIBITOR
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
AU2003231834A1 (en) * 2002-05-24 2003-12-12 Sicor Inc. Aqueous fludarabine phosphate composition
US20080220107A1 (en) * 2002-09-03 2008-09-11 Pharmacure Health Care Ab Nasal spray apparatus
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ITMI20022748A1 (en) * 2002-12-23 2004-06-24 Eurand Int STABILIZED SOLID DISPERSIONS OF DRUG IN AN ORGANIC CAREER AND PROCEDURE FOR THEIR PREPARATION.
PT1608344E (en) * 2003-03-28 2010-09-02 Ares Trading Sa Oral formulations of cladribine
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
EA011099B1 (en) * 2004-03-05 2008-12-30 Кембридж Байотекнолоджи Лимитед Therapeutic compounds
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1917011A1 (en) * 2005-08-26 2008-05-07 Antisoma PLC Combinations comprising dmxaa for the treatment of cancer
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
DE102006006532B4 (en) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmaceutical preparation
EP2057985B1 (en) * 2006-06-13 2013-10-16 Nippon Shinyaku Co., Ltd. Tablet coated with a polyvinyl alcohol copolymer
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
EA201190243A1 (en) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани STABLE PHARMACEUTICAL COMPOSITION OF FLUDARABIN PHOSPHATE
EP2428201A1 (en) * 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7464B (en) * 1973-01-16 1974-11-27 J Voorhees Treatment of proliferating skin diseases with papavine alkaloids
US3923785A (en) 1974-04-22 1975-12-02 Parke Davis & Co (R)-3-(2-deoxy-{62 -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo{8 4,5-d{9 {8 1,3{9 diazepin-8-ol
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4163839A (en) 1977-12-09 1979-08-07 Zaidan Hojin Biselbutsu Kagaku Kenkyu Kai Isocoformycin and a process for the production thereof
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
JPS57209225A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
JPS5920219A (en) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd Preparation of enteric coated pharmaceutical
JPS5951223A (en) * 1982-09-17 1984-03-24 Sumitomo Chem Co Ltd Pharmaceutical composition
US4713372A (en) 1984-03-16 1987-12-15 Warner-Lambert Company 2-chloropentostatin compound having adenosine diaminase inhibitory activity
US5254539A (en) * 1985-08-26 1993-10-19 U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health Method of treating HIV with 2',3'-dideoxyinosine
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
JPS649932A (en) * 1987-07-01 1989-01-13 Toyo Capsel Kk Soft capsule preparation using newly combined component as the base
US5521162A (en) 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US5132291A (en) 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
JPH04501857A (en) * 1989-05-15 1992-04-02 アメリカ合衆国 How to treat hepatitis
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06316524A (en) * 1992-09-11 1994-11-15 Naoyuki Inoue Anti-aids virus agent
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5366960A (en) 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5635156A (en) 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5663155A (en) 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
JPH09100226A (en) * 1995-10-03 1997-04-15 Sumitomo Pharmaceut Co Ltd Production of sustained release enteric coating preparation
WO1998042352A1 (en) * 1997-03-24 1998-10-01 Glaxo Group Ltd. Method for treating b-cell tumors with ara-g nucleoside derivatives
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP2651658B1 (en) * 2010-12-14 2015-02-25 Hendrickson USA, L.L.C. Head plate for vehicle axle

Also Published As

Publication number Publication date
WO2000025758A1 (en) 2000-05-11
DE69940674D1 (en) 2009-05-14
JP5523647B2 (en) 2014-06-18
IL142801A (en) 2006-04-10
DK1126828T3 (en) 2009-06-15
MXPA01004547A (en) 2003-07-21
JP2011057712A (en) 2011-03-24
AU774055B2 (en) 2004-06-17
CA2347913C (en) 2010-09-14
EP1126828B1 (en) 2009-04-01
US6174873B1 (en) 2001-01-16
ES2322724T3 (en) 2009-06-25
JP5580726B2 (en) 2014-08-27
EP1126828A1 (en) 2001-08-29
IL142801A0 (en) 2002-03-10
PT1126828E (en) 2009-05-25
AU1711000A (en) 2000-05-22
ATE427103T1 (en) 2009-04-15
JP2002528487A (en) 2002-09-03

Similar Documents

Publication Publication Date Title
CA2347913A1 (en) Oral administration of adenosine analogs
JP2002528487A5 (en)
EP1909770B1 (en) Oral controlled release composition containing levetiracetam
EP0598309B1 (en) Multilayer matrix systems for the controlled release of active principles
EP0279976B1 (en) Pseudoephedrine dosage form
RU2236847C2 (en) Composition as multiple particles with modified release
AU639231B2 (en) Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US6838093B2 (en) System for osmotic delivery of pharmaceutically active agents
US20040131671A1 (en) Sustained release formulations containing acetaminophen and tramadol
KR20030013460A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DE3363321D1 (en) Long-lasting three layered pharmaceutical film preparations
WO1993003711A1 (en) Dosage form for delivering drug in short-time period
CN102170877A (en) Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers
WO2009069089A1 (en) Levetiracetam controlled release composition
EP1191925B1 (en) Sustained release dosage form unit having latex coating and method of making the same
WO2006117803A2 (en) Transmucosal drug delivery systems
JP4015184B2 (en) Dispenser containing a hydrophobic agent
EP0334167B1 (en) Solid medicament containing gallopamil
WO2020210604A1 (en) Sustained release pharmaceutical dosage form of entecavir
US4352791A (en) Potassium replacement therapy
WO2009006299A2 (en) Multi-particulate systems
EP1095651A2 (en) Multipor food protection
JP2006001941A (en) Tablet formulation
WO2020130450A1 (en) Extended-release medical composition containing zaltoprofen
KR0136211B1 (en) Oral drug delivery system using lipophilic polymer matrix containing hydrophilic polymer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181101